Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 110   

Articles published

SHP 4,673.25 -8.75 (-0.19%)
price chart
Shire Plc (SHPG) Weighing Bid For NPS Pharmaceuticals (NPSP)
Irish-headquartered Shire plc (NASDAQ:SHPG) is said to be interested in acquiring US-based biotech NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) in an attempt to expand its reach in rare diseases such as gastrointestinal and endocrine disorders, ...
Shire considering bid for NPS Pharmaceuticals: Bloomberg  Reuters
Shire Weighs Offer for NPS Pharma  Businessweek
Related articles »  
Is It Too Late To Buy Shire PLC, Hikma Pharmaceuticals Plc and SkyePharma ...
Shire has an attractive 37% operating margin, minimal debt, and generates a lot of free cash flow, which it can use to fund R&D and shareholder returns.
Related articles »  
Why Shire PLC Has Beaten AstraZeneca plc And GlaxoSmithKline plc In 2014
If you invest in pharmaceuticals, Shire (LSE: SHP) is the one you should have bought this year. It's up 60% in the past 12 months to 4,395p, easily beating the FTSE 100's big two - AstraZeneca (LSE: AZN) (NYSE: AZN.
Bank of America Lowers GlaxoSmithKline plc to Underperform (GSK)  Ticker Report
Related articles »  
Why the Earnings Streak Will Continue for Shire plc (SHPG) - Tale of the Tape
Looking for a stock that might be in a good position to beat earnings at its next report? Consider Shire plc ( SHPG ), a firm in the Medicine-Drugs industry, which could be a great candidate for another beat.
Jefferies Group Reiterates "Buy" Rating for Shire PLC (SHP)
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.
Credit Suisse Reaffirms "Neutral" Rating for Shire PLC (SHP)  Dakota Financial News
Shire PLC Rating Reiterated by Credit Suisse (SHPGY)  Ticker Report
Related articles »  
Shire PLC (SHPG) Unveils Plans To Add $3 Billion In Product Sales By 2020
Shire PLC (ADR) (NASDAQ:SHPG) updated the investment community on its pipeline for rare diseases and other specialty conditions at the Research and Development (R&D) Day hosted by the company yesterday.
Shire CEO eyes deals, but no urgency to spend AbbVie breakup fee  Reuters
Shire sees experimental drugs adding $3B to sales by 2020  Chicago Daily Herald
Related articles »  
Shire PLC Rating Reiterated by Citigroup Inc. (SHP)
Citigroup Inc. reaffirmed their buy rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Thursday.
Shire PLC's Buy Rating Reaffirmed at Citigroup Inc. (SHP)
Shire PLC logo Shire PLC (LON:SHP)'s stock had its �buy� rating reissued by research analysts at Citigroup Inc. in a report released on Thursday.
Shire PLC Stock Rating Reaffirmed by Deutsche Bank (SHPGY)
Deutsche Bank restated their buy rating on shares of Shire PLC (NASDAQ:SHPGY) in a report issued on Friday. Deutsche Bank has also updated their ratings on a number of other healthcare stocks in the last week.
Shire PLC Receives Buy Rating from Jefferies Group (SHPGY)  Ticker Report
Shire PLC Rating Reiterated by Deutsche Bank (SHP)  The Legacy
Related articles »  
Shire PLC's "Buy" Rating Reaffirmed at Deutsche Bank (SHP)
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.
Shire PLC Rating Reiterated by JPMorgan Chase & Co. (SHP)  WKRB News
Persimmon plc Stock Rating Lowered by Citigroup Inc. (PSN)  Ticker Report
Related articles »